Guggenheim analyst Etzer Darout named Zymeworks (ZYME) a Best Idea for 2020 and reiterates a Buy rating on the shares with a $54 price target. The company yesterday announced an agreement with Pfizer (PFE) and the initiation of a Phase 2 trial that will evaluate ZW25 in combination with Ibrance for patients with advanced HER2 and HR-positive breast cancer, Darout tells investors in a research note. The Phase 2 initiation is incremental to the Buy thesis, says the anlayst, who notes that Zymeworks now has two ongoing Phase 2 studies in breast and gastric cancers with ZW25 and a Phase 1 study with its anti-HER2 bispecific antibody drug conjugate, ZW49. Darout expects positive news flow to drive share appreciation over the next 12-18 months.